Provided by
| Consensus (mean) in EUR million | FY 2025 | FY 2026 E | FY 2027 E | FY 2028 E |
|---|---|---|---|---|
| Orders received | 5,216 | 4,893 | 5,401 | 5,683 |
| - Biomaterial Solutions and Services | 3,716.0 | 3,247.4 | 3,547.0 | 3,738.2 |
| - Process Performance Solutions | 1,500.0 | 1,646.2 | 1,853.7 | 1,945.0 |
| Net sales | 5,197 | 5,265 | 5,393 | 5,621 |
| - Biomaterial Solutions and Services | 3,716.0 | 3,661.0 | 3,574.2 | 3,669.4 |
| - Process Performance Solutions | 1,481.0 | 1,607.7 | 1,794.2 | 1,879.3 |
| Comparable EBITA | 620 | 618 | 681 | 731 |
| - Biomaterial Solutions and Services | 381.0 | 352.9 | 383.4 | 408.8 |
| - Process Performance Solutions | 290.0 | 310.2 | 342.4 | 365.1 |
| Comparable EBITA Margin (%) | 11.9% | 11.7% | 12.6% | 13.0% |
| - Biomaterial Solns. and Servs. | 10.3% | 9.6% | 10.7% | 11.1% |
| - Process Perf. Solns. | 19.6% | 19.3% | 19.1% | 19.4% |
| Adjusted EPS | 1.82 | 2.02 | 2.29 | 2.51 |
| Dividend per share | 1.35 | 1.41 | 1.49 | 1.57 |